Servier Pharmaceuticals is a commercial-stage biotech company with current treatments for patients with acute lymphoblastic leukemia (ALL). Driven by discovery in oncology and potentially other areas of unmet medical need, we leverage Servier Group’s global portfolio and seek acquisitions, licensing deals and partnerships. We are poised to be an innovative leader serving U.S. patients and caregivers.

Servier Pharmaceuticals is a U.S. subsidiary of Servier Group, a unique international pharmaceutical group governed by a non-profit foundation. As a privately held company, we have the freedom to maintain a steady focus on the most urgent needs of patients. Our independence allows us to be more forward thinking and make sustainable choices for the long-term.

Coupled with the unique resources of Servier BioInnovation, Servier Group’s external R&D initiative, we are exploring a broad spectrum of therapeutic innovation – from the earliest research stages through commercialization.

SERVIER PHARMACEUTICALS AT A GLANCE

• 100+

  Employees
• 10+

  Partnerships

SERVIER PHARMACEUTICALS LEADERSHIP TEAM

• 
  David K. Lee
  Chief Executive Officer
• 
  Raffaele Baffa
  Chief Medical Officer
• 
  Michael Bolton
  General Counsel
• 
  Erik Lemay
  Head of Technical Operations
• 
  Wendy Poage
  Head of Patient Advocacy
• 
  Deniz Razon
  Head of Commercial
• 
  Kelly Schlemm
  Head of Communications & Public Affairs
• 
  Samantha Small
  Chief of Staff
• 
  Latarsha Stewart
  Head of Compliance
• 
  Bart Van Rhijn
  Head of Finance
• 
  Donna Vieraitis
  Head of Human Resources
• 
  Mark Yunger
  Head of IT

OUR ETHICS & COMPLIANCE PROGRAM

Servier Pharmaceuticals is committed to complying with all applicable laws and regulations as well as industry codes and standards. We seek to make therapeutic progress to serve patient needs with integrity and through an effective culture of ethics and compliance.

Our Ethics & Compliance Program has been developed to be in accordance with the U.S. Department of Health and Human Services Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers which was published in 2003. We have also adopted and developed policies, procedures and guidelines to foster compliance with the Pharmaceutical Research and Manufacturers of America (“PhRMA”) Code on Interactions with Healthcare Professionals.

Key elements of the Servier Pharmaceuticals Ethics & Compliance Program include but are not limited to:

• Written policies, procedures and standards of conduct
• Designated compliance officer and compliance committee
• Effective training, education and lines of communication
• Internal monitoring and auditing
• Establishing and enforcing standards through well-publicized disciplinary guidelines
• Promptly responding to detected offenses and undertaking corrective action

California Comprehensive Compliance Program Annual Declaration

PIPELINE & PRODUCTS

We are committed to building a robust portfolio of treatments starting with oncology and potentially expanding to other therapeutic areas.

Advancing innovation for patients is at the heart of everything we do. Globally we devote 25 percent of our total revenue, excluding generics, to researching and developing new therapies that bring real value to patients and caregivers. Our robust pipeline includes more than a dozen oncology projects at varying stages of clinical development.

Please note that this is a comprehensive pipeline that includes both U.S. and global compounds (not all of these items are available in the U.S.).

OUR NETWORK

PARTNERS

We believe collaboration and co-creation are fundamental to driving innovation. We are actively building the kinds of alliances that bring solutions to patients’ lives and can accelerate access to therapies.

SERVIER GROUP

Servier Group is a unique international pharmaceutical company governed by a non-profit foundation with its headquarters in Suresnes, France. The group has a presence in 149 countries and 21,700 employees worldwide.

Learn more about Servier Group